US Stock Insider Trading | Solid Biosciences disclosed 6 insider transactions on February 2

K-LinePoet · 2026-02-04T21:43:35+00:00

On February 2, 2026, Solid Biosciences disclosed insider trading activities involving several executives and directors, with Cumbo Alexander selling 80,300 shares. The company focuses on gene therapy, dedicated to improving the lives of patients with rare neuromuscular and cardiac diseases.

K-LinePoet

2026-02-04 21:43:35

Abstract generation in progress

On February 2, 2026, Solid Biosciences (SLDB) disclosed six insider trading transactions. Director Cumbo Alexander sold 80,300 shares on February 2, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Brooks Gabriel	February 2, 2026	Sell	23,000	6.44	182,400
February 2, 2026	Executive	Herzich Paul	February 2, 2026	Sell	26,300	6.44	169,000
February 2, 2026	Executive	Tan Kevin	February 2, 2026	Sell	26,800	6.44	172,700
February 2, 2026	Director	Cumbo Alexander	February 2, 2026	Sell	80,300	6.44	516,600
February 2, 2026	Executive	Howton David T	February 2, 2026	Sell	37,800	6.44	243,100
February 2, 2026	Executive	Hanrahan Jessie	February 2, 2026	Sell	26,500	6.44	170,800
January 13, 2026	Executive	Tan Kevin	January 13, 2026	Sell	5,704	5.27	30,100
January 6, 2026	Director	Ganot Ilan	January 5, 2026	Sell	1,053	5.43	5,717.79
December 4, 2025	Executive	Hanrahan Jessie	December 3, 2025	Sell	4,483	5.11	22,900
December 4, 2025	Executive	Herzich Paul	December 3, 2025	Sell	2,701	5.11	13,800

【Company Information】

Solid Biosciences Inc., formerly known as “SOLID Ventures Management, LLC,” was established in March 2013 as a Delaware limited liability company. The company is a life sciences firm focused on advancing current and future gene therapy candidate drugs, collectively referred to as candidates, including SGT-003 for Duchenne muscular dystrophy, or Duchenne, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and additional assets for treating heart and other diseases at various stages of development with different levels of investment. The company is developing a diversified pipeline involving rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-centered and founded by individuals directly affected by Duchenne, the company’s mission is to improve the daily lives of patients suffering from these devastating diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.